{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:44:21Z","timestamp":1790174661032,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"22","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2018,3,28]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Two recent randomised trials studied the benefit of mineralocorticoid receptor antagonists (MRAs) in ST-segment elevation myocardial infarction (STEMI) irrespective or in absence of heart failure. The studies were both undersized to assess hard clinical endpoints. A pooled analysis was preplanned by the steering committees.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prespecified meta-analysis of patient-level data of patients with STEMI recruited in two multicentre superiority trials, randomised within 72\u2009hours after symptom onset. Patients were allocated (1:1) to two MRA regimens: (1) an intravenous bolus of potassium canrenoate (200\u2009mg) followed by oral spironolactone (25\u2009mg once daily) versus standard therapy or (2) oral eplerenone (25\u201350\u2009mg) versus placebo. The primary and key secondary outcomes, all-cause death and the composite of all-cause death or resuscitated sudden death, respectively, were assessed in the intention-to-treat population using a Cox model stratified on the study identifier.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients were randomly assigned to receive (n=1118) or not the MRA regimen (n=1123). After a median follow-up time of 188 days, the primary and secondary outcomes occurred in 5 (0.4%) and 17 (1.5%) patients (adjusted HR (adjHR) 0.31, 95%\u2009CI 0.11 to 0.86, p=0.03) and 6 (0.5%) and 22 (2%) patients (adjHR 0.26, 95%\u2009CI 0.10 to 0.65, p=0.004) in the MRA and control groups, respectively. There were also trends towards lower rates of cardiovascular death (p=0.06) and ventricular fibrillation (p=0.08) in the MRA group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our analysis suggests that compared with standard therapy, MRA regimens are associated with a reduction of death and death or resuscitated sudden death in STEMI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2018-312950","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T12:20:47Z","timestamp":1524658847000},"page":"1843-1849","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction"],"prefix":"10.1136","volume":"104","clinical-trial-number":[{"clinical-trial-number":"nct01176968","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Farzin","family":"Beygui","sequence":"first","affiliation":[{"name":"ACTION Study Group, Service de Cardiologie, Centre Hospitalier Universitaire de Caen, EA4650 Normandie Universit\u00e9, Caen, Basse-Normandie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Belle","sequence":"additional","affiliation":[{"name":"INSERM U1011 and Cardiology, Institut Coeur Poumon, CHRU de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ecollan","sequence":"additional","affiliation":[{"name":"SAMU, ACTION Study Group, Centre Hospitalier Universitaire Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Machecourt","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, Rh\u00f4ne-Alpes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W","family":"Hamm","sequence":"additional","affiliation":[{"name":"Kerckhoff Clinic, Bad Nauheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estaeban","family":"Lopez De Sa","sequence":"additional","affiliation":[{"name":"La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Flather","sequence":"additional","affiliation":[{"name":"Cardiology, University of East Anglia and Norfolk and Norwich University Hospital, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W A","family":"Verheugt","sequence":"additional","affiliation":[{"name":"Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"ACTION Study Group, Unite de Recherche Clinique, H\u00f4pital Lariboisi\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm CIC 1433 and Cardiology, Centre Hospitalier Universitaire de Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan Hospital, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[{"name":"Cardiology, Sorbonne Universit\u00e9-Paris 6, ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Piti\u00e9-Salp\u00eatri\u0117re, INSERM UMRS 1166, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"2025091921343374000_104.22.1843.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.634626"},{"key":"2025091921343374000_104.22.1843.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn383"},{"key":"2025091921343374000_104.22.1843.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.12.013"},{"key":"2025091921343374000_104.22.1843.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.04.019"},{"key":"2025091921343374000_104.22.1843.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp301"},{"key":"2025091921343374000_104.22.1843.6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.100941"},{"key":"2025091921343374000_104.22.1843.7","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000138973.55605.38"},{"key":"2025091921343374000_104.22.1843.8","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068340.96506.0F"},{"key":"2025091921343374000_104.22.1843.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.03.032"},{"key":"2025091921343374000_104.22.1843.10","first-page":"1014","article-title":"[Value of potassium canrenoate in the prevention of arrhythmia during the acute phase of myocardial infarction]","volume":"72","author":"Denis","year":"1979","journal-title":"Arch Mal Coeur Vaiss"},{"key":"2025091921343374000_104.22.1843.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.11.076"},{"key":"2025091921343374000_104.22.1843.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2025091921343374000_104.22.1843.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492"},{"key":"2025091921343374000_104.22.1843.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"2025091921343374000_104.22.1843.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu164"},{"key":"2025091921343374000_104.22.1843.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.033"},{"key":"2025091921343374000_104.22.1843.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.010"},{"key":"2025091921343374000_104.22.1843.18","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.136242"},{"key":"2025091921343374000_104.22.1843.19","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.111258"},{"key":"2025091921343374000_104.22.1843.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs104"},{"key":"2025091921343374000_104.22.1843.21","first-page":"e78","article-title":"ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"2013","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025091921343374000_104.22.1843.22","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"2014","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025091921343374000_104.22.1843.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp136"},{"key":"2025091921343374000_104.22.1843.24","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(93)90656-T"},{"key":"2025091921343374000_104.22.1843.25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/oxfordjournals.eurheartj.a060995","article-title":"Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition","volume":"16","author":"Foy","year":"1995","journal-title":"Eur Heart J"},{"key":"2025091921343374000_104.22.1843.26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2017.09.010","article-title":"Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials","volume":"195","author":"Bossard","year":"2018","journal-title":"Am Heart J"},{"key":"2025091921343374000_104.22.1843.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.600"},{"key":"2025091921343374000_104.22.1843.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908103210629"},{"key":"2025091921343374000_104.22.1843.29","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.amjcard.2017.03.013","article-title":"Incidence and Prognostic Impact of Heart Failure Hospitalization During Follow-Up After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction","volume":"119","author":"Taniguchi","year":"2017","journal-title":"Am J Cardiol"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2018-312950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:34:45Z","timestamp":1758342885000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2018-312950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":29,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2018,10,26]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/heartjnl-2018-312950"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2018-312950","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]}}}